CalciMedica (NASDAQ:CALC) Shares Down 2%

CalciMedica, Inc. (NASDAQ:CALC - Get Free Report)'s share price fell 2% during trading on Monday . The company traded as low as $4.65 and last traded at $4.89. 30,659 shares were traded during trading, a decline of 6% from the average session volume of 32,587 shares. The stock had previously closed at $4.99.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CALC. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of CalciMedica in a research note on Tuesday, August 13th. Singular Research upgraded CalciMedica to a "moderate buy" rating in a research note on Friday, June 28th. Finally, Oppenheimer raised their target price on CalciMedica from $14.00 to $20.00 and gave the company an "outperform" rating in a report on Wednesday, July 10th.

CalciMedica Price Performance

The company has a market cap of $50.52 million, a PE ratio of -2.12 and a beta of 1.27. The firm has a 50-day simple moving average of $4.38 and a two-hundred day simple moving average of $4.65.

CalciMedica (NASDAQ:CALC - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.03. Equities research analysts forecast that CalciMedica, Inc. will post -2.21 EPS for the current year.

Insider Activity at CalciMedica

In other news, Director Robert N. Wilson bought 54,000 shares of the stock in a transaction on Friday, August 23rd. The stock was purchased at an average cost of $3.72 per share, with a total value of $200,880.00. Following the purchase, the director now owns 364,196 shares of the company's stock, valued at $1,354,809.12. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Robert N. Wilson acquired 8,443 shares of the business's stock in a transaction dated Thursday, June 27th. The shares were acquired at an average cost of $3.23 per share, for a total transaction of $27,270.89. Following the acquisition, the director now directly owns 258,918 shares in the company, valued at approximately $836,305.14. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert N. Wilson bought 54,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average price of $3.72 per share, with a total value of $200,880.00. Following the completion of the acquisition, the director now owns 364,196 shares of the company's stock, valued at approximately $1,354,809.12. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 78,443 shares of company stock valued at $286,491. Company insiders own 53.30% of the company's stock.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.